XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
The Company and Summary of Significant Accounting Policies (Details) (USD $)
 0 Months Ended 3 Months Ended 0 Months Ended 1 Months Ended
Feb. 18, 2015
Mar. 31, 2015
Mar. 31, 2014
Feb. 03, 2014
Feb. 28, 2014
Company Basis of Presentation (Textual) [Abstract]          
Revenues   $ 0us-gaap_Revenues      
Proceeds from the issuance of common stock     9,018,000us-gaap_ProceedsFromIssuanceOfCommonStock    
Notification for delisting of shares   On February 18, 2015, we received notification from Nasdaq of potential delisting of our shares from the Nasdaq Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. Nasdaq rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. In order to remain compliant with the Nasdaq listing standards, the Company expects to effect a reverse stock split of its common stock to increase the market price of the common stock above the Nasdaq minimum bid price listing standard. However, the effect of a reverse stock Split on the market price of the common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of the Company’s common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing the Company’s market capitalization, and there can be no assurance that the market price per post-reverse split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of the Company’s common stock may vary based on other factors that are unrelated to the number of shares outstanding, including the Company’s future performance.      
Minimum closing bid price of common stock $ 1.00abio_ClosingBidPriceOfCommonStock        
Number of grace days provided by NASDAQ to meet continued listing standard 180 days        
Concentrations of credit risk   0us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure      
Registered Direct Offering          
Company Basis of Presentation (Textual) [Abstract]          
Proceeds from the issuance of common stock       $ 8,700,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_SubsidiarySaleOfStockAxis
= abio_RegisteredDirectOfferingMember		 $ 7,900,000us-gaap_ProceedsFromIssuanceOfCommonStock
/ us-gaap_SubsidiarySaleOfStockAxis
= abio_RegisteredDirectOfferingMember
Phase 3 heart failure (HF) trial of Gencaro | BEST Trial          
Company Basis of Presentation (Textual) [Abstract]          
Number of patients   2,708abio_NumberOfPatients
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseThreeHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_BestTrialMember		      
Phase 3 heart failure (HF) trial of Gencaro | GENETIC-AF Trial          
Company Basis of Presentation (Textual) [Abstract]          
Number of patients company plans to enroll   420abio_NumberOfPatientsCompanyPlansToEnroll
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseThreeHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_GENETICAFTrialMember		      
Phase Two B Heart Failure | GENETIC-AF Trial          
Company Basis of Presentation (Textual) [Abstract]          
Number of patients company plans to enroll   200abio_NumberOfPatientsCompanyPlansToEnroll
/ abio_ClinicalTrialsByPhaseAxis
= abio_PhaseTwoBHeartFailureMember
/ us-gaap_HealthCareTrustFundAxis
= abio_GENETICAFTrialMember